MXPA05000781A - Compuesto antitumor y usos terapeuticos del mismo. - Google Patents

Compuesto antitumor y usos terapeuticos del mismo.

Info

Publication number
MXPA05000781A
MXPA05000781A MXPA05000781A MXPA05000781A MXPA05000781A MX PA05000781 A MXPA05000781 A MX PA05000781A MX PA05000781 A MXPA05000781 A MX PA05000781A MX PA05000781 A MXPA05000781 A MX PA05000781A MX PA05000781 A MXPA05000781 A MX PA05000781A
Authority
MX
Mexico
Prior art keywords
therapeutic uses
derivative
antitumor compound
arylidene
fgf
Prior art date
Application number
MXPA05000781A
Other languages
English (en)
Inventor
Marco Alessandro Pierotti
Original Assignee
Cell Therapeutics Europ S Rl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Europ S Rl filed Critical Cell Therapeutics Europ S Rl
Publication of MXPA05000781A publication Critical patent/MXPA05000781A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se expone el uso de un derivado de arilideno 2-indolinona para el tratamiento de tumores, que incluye Met, PDGF-R, FGF-RI, FGF-R3 y un conjunto de tirosina cinasas o las oncoproteina de la familia Ret. La invencion tambien proporciona composiciones farmaceuticas que comprende el derivado de arilideno 2-indolinona, asi como tambien un conjunto que comprende, en recipientes por separado, el derivado y los agente anti-cancer o anti-tumor.
MXPA05000781A 2002-07-23 2003-07-22 Compuesto antitumor y usos terapeuticos del mismo. MXPA05000781A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002MI001620A ITMI20021620A1 (it) 2002-07-23 2002-07-23 Composto ad ativita' antitumorale
PCT/EP2003/007963 WO2004009083A1 (en) 2002-07-23 2003-07-22 Antitumor compound and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
MXPA05000781A true MXPA05000781A (es) 2005-09-21

Family

ID=30130912

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05000781A MXPA05000781A (es) 2002-07-23 2003-07-22 Compuesto antitumor y usos terapeuticos del mismo.

Country Status (12)

Country Link
US (2) US20060258731A1 (es)
EP (1) EP1534271B1 (es)
JP (1) JP2005537277A (es)
CN (1) CN1668298A (es)
AT (1) ATE337001T1 (es)
AU (1) AU2003251437A1 (es)
CA (1) CA2493202A1 (es)
DE (1) DE60307856T2 (es)
ES (1) ES2271649T3 (es)
IT (1) ITMI20021620A1 (es)
MX (1) MXPA05000781A (es)
WO (1) WO2004009083A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005068424A1 (en) * 2004-01-20 2005-07-28 Cell Therapeutics Europe S.R.L. Indolinone derivatives as receptor tyrosine kinase ihibitors
EP1883403A4 (en) * 2005-04-29 2011-02-16 Univ Ohio State Res Found KERATINOCYTE GROWTH FACTOR RECEPTOR TYROSINE-SPECIFIC INHIBITORS FOR THE PREVENTION OF CANCER METASTASE
CA2662591A1 (en) * 2006-09-07 2008-03-13 Astrazenca Ab Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase
PL2350075T3 (pl) 2008-09-22 2014-07-31 Array Biopharma Inc Podstawione związki imidazo[1,2b]pirydazynowe jako inhibitory kinaz Trk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PL3699181T3 (pl) 2014-11-16 2023-05-22 Array Biopharma, Inc. Postać krystaliczna wodorosiarczanu (s)-n-(5-((r)-2-(2,5-difluorofenylo) - pirolidyn-1-ylo)-pirazolo[1,5-a]pirimidyn-3-ylo)-3-hydroksypirolidyno-1-karboksyamidu
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
EP3439663B1 (en) 2016-04-04 2024-07-17 Loxo Oncology, Inc. Methods of treating pediatric cancers
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
GEP20227339B (en) 2016-04-04 2022-01-25 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)- pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydro-xypyrrolidine-1-carboxamide
CA3024603A1 (en) 2016-05-18 2017-11-23 Charles Todd Eary Process for the preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TW202410896A (zh) 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502072A (en) * 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
US6147106A (en) * 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6130238A (en) * 1997-06-20 2000-10-10 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
ME00415B (me) * 2000-02-15 2011-10-10 Pharmacia & Upjohn Co Llc Pirol supstituisani 2-indol protein kinazni inhibitori

Also Published As

Publication number Publication date
EP1534271B1 (en) 2006-08-23
ES2271649T3 (es) 2007-04-16
ATE337001T1 (de) 2006-09-15
CA2493202A1 (en) 2004-01-29
ITMI20021620A1 (it) 2004-01-23
US20060258731A1 (en) 2006-11-16
DE60307856T2 (de) 2007-04-12
WO2004009083A1 (en) 2004-01-29
AU2003251437A8 (en) 2004-02-09
CN1668298A (zh) 2005-09-14
EP1534271A1 (en) 2005-06-01
US20090130229A1 (en) 2009-05-21
DE60307856D1 (de) 2006-10-05
AU2003251437A1 (en) 2004-02-09
WO2004009083A8 (en) 2005-02-03
JP2005537277A (ja) 2005-12-08

Similar Documents

Publication Publication Date Title
MXPA05000781A (es) Compuesto antitumor y usos terapeuticos del mismo.
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
AU2002322280A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
HK1086573A1 (en) Quinazoline derivatives for treatment of cancer
AU2003302892A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
MXPA04004219A (es) Derivados de quinazolina como agentes antitumorales.
AU2002339865A1 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
PL367682A1 (en) Dolastatin 10 derivatives
UA99597C2 (ru) Пиримидилциклопентаны как ингибиторы акт протеинкиназ
MY158054A (en) 4-anilino quinazoline derivatives as antiproliferative agents
HK1087613A1 (en) Quinazoline derivatives and their use in the treatment of cancer
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
GEP20074213B (en) Novel inhibitors of kinases
UA84167C2 (ru) Производные хиназолина как ингибиторы тирозинкиназы, способ их получения (варианты), фармацевтическая композиция на их основе
HRP20050707B1 (hr) Polimorf od {6,7-bis(2-metoksi-etoksi)-kinazolin-4-il}-(3e)
WO2003072059A3 (en) Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
AU2002324451A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
MX2009005011A (es) Imidazopirazinas como inhibidores de proteina quinasa.
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
YU21404A (sh) Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka
AU2003233733A1 (en) Compositions for cancer therapy saponins or sapogenins
AU2002313726A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
UA96427C2 (en) Substituted pyrazole compounds
AU2002253899A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer

Legal Events

Date Code Title Description
FG Grant or registration